Zykadia

Ceritinib (Zykadia) is an oral prescription medicine used to treat certain types of non-small cell lung cancer. It belongs to a class of drugs known as kinase inhibitors. Always consult a healthcare provider for personalized guidance.

Ceritinib is prescribed for adults with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. It works by blocking signals that promote cancer cell growth. Patients often ask, 'what is ceritinib used for' when exploring treatment options for advanced NSCLC. It may be recommended when other treatments have not been effective.

Common effects of ceritinib include gastrointestinal symptoms such as nausea, diarrhea, or vomiting. Some users report fatigue, decreased appetite, or abdominal pain. These effects vary by individual and should be discussed with a healthcare provider if they persist or worsen.

Ceritinib should be taken exactly as prescribed by a healthcare professional. It is important to follow all instructions regarding food intake, as some forms require administration with food. Patients should inform their doctor about all medications and supplements they are taking to avoid potential interactions.

Ceritinib may interact with other drugs, including strong CYP3A inhibitors or inducers, which can affect its effectiveness. Grapefruit products should be avoided while taking ceritinib. Alcohol use should be discussed with a healthcare provider, as it may worsen certain side effects.